Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hypoxia induces DOT1L in articular cartilage to protect against osteoarthritis
Astrid De Roover, Ana Escribano Núñez, Frederique M.F. Cornelis, Chahrazad Cherifi, Leire Casas-Fraile, An Sermon, Frederic Cailotto, Rik J. Lories, Silvia Monteagudo
Astrid De Roover, Ana Escribano Núñez, Frederique M.F. Cornelis, Chahrazad Cherifi, Leire Casas-Fraile, An Sermon, Frederic Cailotto, Rik J. Lories, Silvia Monteagudo
View: Text | PDF
Research Article Aging Bone biology

Hypoxia induces DOT1L in articular cartilage to protect against osteoarthritis

  • Text
  • PDF
Abstract

Osteoarthritis is the most prevalent joint disease worldwide, and it is a leading source of pain and disability. To date, this disease lacks curative treatment, as underlying molecular mechanisms remain largely unknown. The histone methyltransferase DOT1L protects against osteoarthritis, and DOT1L-mediated H3K79 methylation is reduced in human and mouse osteoarthritic joints. Thus, restoring DOT1L function seems to be critical to preserve joint health. However, DOT1L-regulating molecules and networks remain elusive, in the joint and beyond. Here, we identified transcription factors and networks that regulate DOT1L gene expression using a potentially novel bioinformatics pipeline. Thereby, we unraveled a possibly undiscovered link between the hypoxia pathway and DOT1L. We provide evidence that hypoxia enhanced DOT1L expression and H3K79 methylation via hypoxia-inducible factor-1 α (HIF1A). Importantly, we demonstrate that DOT1L contributed to the protective effects of hypoxia in articular cartilage and osteoarthritis. Intra-articular treatment with a selective hypoxia mimetic in mice after surgical induction of osteoarthritis restored DOT1L function and stalled disease progression. Collectively, our data unravel a molecular mechanism that protects against osteoarthritis with hypoxia inducing DOT1L transcription in cartilage. Local treatment with a selective hypoxia mimetic in the joint restores DOT1L function and could be an attractive therapeutic strategy for osteoarthritis.

Authors

Astrid De Roover, Ana Escribano Núñez, Frederique M.F. Cornelis, Chahrazad Cherifi, Leire Casas-Fraile, An Sermon, Frederic Cailotto, Rik J. Lories, Silvia Monteagudo

×

Figure 5

DOT1L contributes to the protective effects of hypoxia in human articular chondrocytes.

Options: View larger image (or click on image) Download as PowerPoint
DOT1L contributes to the protective effects of hypoxia in human articula...
(A) Real-time PCR analysis of DOT1L and VEGF in primary human articular chondrocytes (hACs) after treatment with hypoxia mimetic IOX2 or vehicle (V) at the indicated concentrations for 72 hours (n = 3, *P < 0.05, ****P < 0.0001, Holm corrected for 10 tests by generalized least squares model). (B) Real-time PCR analysis of DOT1L and VEGF in primary hACs cultured in normoxic (21% O2) or hypoxic (1% O2) conditions for 14 days (n = 3, **P < 0.01 by paired t test). (C) Real-time PCR analysis of COL2A1 and ACAN in primary hACs after treatment with IOX2 at the indicated concentrations or V for 72 hours (n = 3, *P < 0.05, **P < 0.01, ****P < 0.0001, Holm corrected for 10 tests by generalized least squares model). (D) Real-time PCR analysis of COL2A1 and ACAN in primary hACs cultured in normoxic (21%O2) or hypoxic (1%O2) conditions for 14 days (n = 3, **P < 0.01 by paired t test). (E) Real-time PCR analysis of COL2A1, ACAN, and TCF1 in primary hACs after treatment with hypoxia mimetic IOX2 (20 μM) or V and siRNA-mediated silencing of DOT1L (siDOT1L) or scrambled control (siSCR) for 72 hours (n = 3, P < 0.05, Šidák corrected for 6 tests in 2-way ANOVA). (F) Real-time PCR analysis of COL2A1, ACAN, and TCF1 in primary hACs cultured in normoxic (21%O2) or hypoxic (1%O2) conditions for 14 days and siRNA-mediated silencing of DOT1L or siSCR (n = 3, *P < 0.05, Šidák corrected for 6 tests in 2-way ANOVA). (G) Alcian blue staining of primary hAC micromasses cultured in normoxic (21%O2) or hypoxic (1%O2) conditions treated with V or DOT1L inhibitor EPZ-5676 (EPZ) for 14 days. Images are representative of 3 independent experiments with technical triplicates. Quantification of staining relative to V in normoxic conditions was determined by colorimetry at 595 nm (n = 3, *P < 0.05 Šidák corrected for 6 tests in 2-way ANOVA). Data are shown as the mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts